Abstract
Objectives To present the first Australian case report of COVID-19 associated Miller Fisher Syndrome.
Methods A literature search was performed using PubMed with the key words of ‘Miller Fisher Syndrome’ AND ‘COVID-19’ OR ‘SARS-CoV-2’. Consent was obtained from the patient and clinical details were retrieved using the Integrated Electronic Medical Record (ieMR).
Results The associated between COVID-19 and Guillain-Barré Syndrome (GBS) has been reported in previous studies, however the occurrence of the Miller Fisher Syndrome (MFS) in the setting of acute COVID-19 infection is rare. Most of these cases are reported in Europe and the United States of America (USA).1 To our knowledge, no Australian cases of COVID-19 associated MFS have been reported.2 We present here, the first Australian case report of a patient presenting to the emergency department with the cardinal features of MFS with concurrent acute COVID-19 infection. He was found to be antiganglioside antibody positive and treated with two courses of intravenous immunoglobulin with eventual full neurological recovery.
Conclusions Miller Fisher Syndrome is a rare presentation of COVID-19 infection. Given the enduring prevalence of COVID-19 in the community, clinicians should be mindful of rarer neurological presentations as in this reported case.
References
Martins-Filho PR, Pereira de Andrade AL, Pereira de Andrade AJ, Moura da Silva MD, de Souza Araújo AA, Nunes PS, Santos VS, Ferreira LC, de Aquino Neves EL, Quintans-Júnior LJ. Miller Fisher Syndrome in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Systematic Review. Journal of Clinical Neurology (Seoul, Korea). 2021;17(4):541–545. https://doi.org/10.3988/jcn.2021.17.4.541
Biswas S, Ghosh R, Mandal A, Pandit A, Roy D, Sengupta S, De K, Swaika BC, Benito-León J. COVID-19 Induced Miller Fisher Syndrome Presenting With Autonomic Dysfunction: A Unique Case Report and Review of Literature. The Neurohospitalist, 2022;12(1):111–116. https://doi.org/10.1177/19418744211016709
